“ Idorsia is able to fully leverage the excellent R&D pipeline that was created at Actelion. The Board has great confidence in the team and I am convinced that their tremendous track record is going to continue to translate into value creation for all.”
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.
We have more ideas, we see more opportunities and we want to help more patients.
> 1 bn Swiss francs in cash
> 550 state-of-the-art laboratory workplaces
> 650 highly qualified professionals
On Day 1
Happy Holidays!
> 10 compounds in the pipeline
With the rich collection of compounds
brought over from Actelion, the Idorsia
teams are now working hard to advance the company’s highly innovative pipeline and further enhance the value proposition
from these assets. Discussions with health authorities are progressing well, so that key compounds are expected to move into latestage development in the coming year.
As investment will be essential in the coming years, we are fortunate to be starting out with 1 billion in cash, and our business development activities have led to additional cash injections. However, until we are generating our own revenue and are truly sustainable, we must be highly cost conscious. This message is constantly repeated at all levels of Idorsia, and our teams are well aware that they are expected to achieve ambitious targets, to work in an ethical manner, and to keep a keen eye on the bottom line.
We have a great team of brilliant scientists and while Idorsia is new, we have been a team for a long time. We have a common approach: novel projects that will answer medical problems in a truly groundbreaking
way, balanced with less risky projects where we have a deep understanding of the disease mechanisms. Our people have the entrepreneurial spirit in their DNA and they are open to smart risk-taking.
For Idorsia, the process which begins with drug discovery and preclinical development ends, we hope, with a novel molecule that will help patients in diseases which still have a high medical need.
- Jean-Pierre Garnier, Chairman